Convection-enhanced drug delivery for gliomas

Surgical Neurology International

Volumn 6, Issue 2, 2015, Pages S59-S67

  Healy, Andrew ^a   Vogelbaum, Michael ^b  

^a Neurosurgical Resident Department of Neurological Surgery Brain Tumor and Neuro Oncology Center   (United States)

^b Brain Tumor and Neuro oncology Center   (United States)

Author keywords

Blood brain barrier; Central nervous system; Chemotherapy; Convection enhanced drug delivery; Glioma

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BLOOD BRAIN BARRIER; CANNULA; CANNULA NUMBER; CANNULA SHAPE; CANNULA SIZE; CATHETER PLACEMENT; CATHETERIZATION; CONVECTION ENHANCED DRUG DELIVERY; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG METABOLISM; GLIOMA; HUMAN; IMAGING AND DISPLAY; INFUSION RATE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REAL TIME IMAGING; TISSUE PRESSURE; TISSUE STRUCTURE; VOLUME; VOLUME OF DISTRIBUTION;

EID: 84930404367     PISSN: None     EISSN: 21527806     Source Type: Journal    
DOI: 10.4103/2152-7806.151337     Document Type: Article

References (72)

1. Anderson RC, Kennedy B, Yanes CL, Garvin J, Needle M, Canoll P, et al . Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. J Neurosurg Pediatr 2013;11:289-95.
2. Barua NU, Woolley M, Bienemann AS, Johnson D, Wyatt MJ, Irving C, et al . Convection-enhanced delivery of AAV2 in white matter- A novel method for gene delivery to cerebral cortex. J Neurosci Methods 2013;220:1-8.
3. Bernal GM, LaRiviere MJ, Mansour N, Pytel P, Cahill KE, Voce DJ, et al . Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine 2014;10:149-57.
4. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfeld EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci 1994;91:2076-80.
5. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahanatra AK, Suri A et al. Targeted therapy for high-grade glioma with the TGF-ß2 inhibitor trabedersen: Results of a randomized and controlled phase IIb study. Neuro Oncol 2011;13:132-42.
6. Bouvier G, Penn RD, Kroin JS, Béique RA, Guérard MJ, Lesage J. Stereotactic administration of intratumoral chronic chemotherapy of recurrent malignant gliomas. Appl Neurophysiol 1987;50:223-6.
7. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al . Placebo-controlled trial of safety and effcacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;345:1008-12.
8. Bruce JN, Fine RL, Canoll P, Yun J, Kennedy BC, Rosenfeld SS, et al. Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 2011;69:1272-9.
9. CarpentierA,Metellus P,Ursu R,ZoharS, Laftte F,Barrie M, et al . Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: A phase II study. Neuro Oncol 2010;12:401-8.
10. Carson BS, Wu QZ, Tyler B, Sukay L, Raychaudhuri R, DiMeco F, et al . New approach to tumor therapy for inoperable areas of the brain: Chronic intraparenchymal drug delivery. J Neuro Oncol 2002;60:151-8.
11. Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, et al . Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol 2013;15:189-97.
12. Corem-Salkmon E, Ram Z, Daniels D, Perlstein B, Last D, Salomon S, et al . Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles. Int J Nanomed 2011;6:1595-602.
13. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al . Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-10.
14. Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, Larson RF, et al . Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: Laboratory investigation. J Neurosurg 2008;108:989-98.
15. Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 2008;5:123-7.
16. Geer CP, Grossman SA. Interstitial fuid fow along white matter tracts: A potentially important mechanism for the dissemination of primary brain tumors. J Neurooncol 1997;32:193-201.
17. Guarnieri M, Carson BS, Khan A Penno M, Jallo GI. Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues. J Neurosci Methods 2004;144:147-52.
18. Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, et al . EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 2010;70:6303-12.
19. Hall WA, Sherr GT. Convection-enhanced delivery of targeted toxins for malignant glioma. Expert Opin Drug Deliv 2006;3:371-7.
20. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999;1:241-63.
21. Krauze MT, Saito R, Noble C, Tamas M, Bringas J, Park JW, et al . Refux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 2005;103:923-9.
22. Krauze MT, McKnight TR, Yamashita Y Bringas J, Noble CO, Saito R, et al . Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc 2005;16:20-6.
23. Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res 1995;680:196-206.
24. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Neuwelt EA. Increasing volume of distribution to the brain with interstitial infusion: Dose, rather than convection, might be the most important factor. Neurosurgery 1996;38:746-52.
25. Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, et al . Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 2010;12:871-81.
26. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, et al . Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007;25:837-44.
27. Laske DW,Youle RJ,Oldfeld EH.Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997;3:1362-8.
28. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg 2004;100:472-9.
29. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995;82:1021-9.
30. Linninger AA, Somayaji MR, Mekarski M, Zhang L. Prediction of convection-enhanced drug delivery to the human brain. J Theor Biol 2008;250:125-38.
31. Lonser RR, Gogate N, Morrison PF,Wood JD, Oldfeld EH. Direct convective delivery of macromolecules to the spinal cord. J Neurosurg 1998;89:616-22.
32. Lonser RR, Walbridge S, Garmestani K, Butman JA, Walters HA, Vortmeyer AO, et al . Successful and safe perfusion of the primate brainstem: In vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 2002;97:905-13.
33. Lonser RR, Warren KE, Butman JA, Quezado Z, Robison RA, Walbridge S, et al . Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg 2007;107:190-7.
34. Mackay JA, Deen DF, Szoka FC Jr. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 2005;1035:139-53.
35. Mardor Y, Last D, Daniels D, Shneor R, Maier SE, Nass D, et al . Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): Increased distribution and magnetic resonance monitoring. J Pharmacol Exp Ther 2009;330:520-5.
36. Mardor Y, Rahav O, Zauberman Y, Lidar Z, Ocherashvilli A, Daniels D, et al . Convection-enhanced drug delivery: Increased efficacy and magnetic resonance image monitoring. Cancer Res 2005;65:6858-63.
37. Morrison PF, Dedrick RL. Transport of cisplatin in rat brain following microinfusion: An analysis. J Pharm Sci 1986;75:120-8.
38. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL. Highflow microinfusion: Tissue penetration and pharmacodynamics. Am J Physiol 1994;266:292-305.
39. Mueller S, Polley MY Lee B, Kunwar S, Pedain C, Wembacher-Schroder E, et al . Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol 2011;101:267-77.
40. Nicholson C, Tao L. Hindered diffusion of high molecular weight compounds in brain extracellular microenvironment measured with integrative optical imaging. Biophys J 1993;65:2277-90.
41. Oh S, Odland R, Wilson SR, Kroeger KM, Liu C, Lowenstein PR, et al . Improved distribution of small molecules and viral vectors in the murine brain using a hollow fber catheter.J Neurosurg 2007;107:568-77.
42. Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, et al . Saftey and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery 2005;56:1243-52.
43. Pollina J, Plunkett RJ, Ciesielski MJ, Lis A, Barone TA, Greenberg SJ, et al . Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model. J Neurooncol 1998;39:217-25.
44. Raghavan R, Brady ML, Rodriguez-Ponce MI, Hartlep A, Pedain C, Sampson JH. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 2006;20:E12.
45. Rapoport SI, editor. Blood-brain barrier in physiology and medicine. New York: Raven Press; 1976. p. 99-111.
46. Rapoport SI. Osmotic opening of the blood-brain barrier: Principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000;20:217-30.
47. Rosca EV, Stukel JM, Gillies RJ,Vagner J, Caplan MR. Specifcity and mobility of biomacromolecular, multivalent constructs for cellular targeting. Biomacromolecules 2007;8:3830-5.
48. Saito R, Sonoda Y, Kumabe T, Nagamatsu K, Watanabe M, Tominaga T Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride. Case report. J Neurosurg Pediatr 2011;7:522-6.
49. Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, et al . Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 2008;10:320-9.
50. Sampson JH, Brady MI, Petry NA, Croteau D, Friedman AH, Friedman HS, et al . Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: Descriptive effects of target anatomy and catheter positioning. Neurosurgery 2007;60:89-98.
51. Sampson JH, Brady M, Raghavan R, Mehta AI, Friedman AH, Reardon DA, et al . Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery 2011;69:668-76.
52. Sampson JH, Raghavan R, Brady MI, Provenzale JM, Herndon JE 2nd, Croteau D, et al. Clinical utility of a patient-specifc algorithm for simulating intracerebral drug infusions. Neuro Oncol 2007;9:343-53.
53. Sampson JH, Raghavan R, Provenzale JM, Croteau D, Reardon DA, Coleman RE, et al. Induction of hyperintense signal on T2-Weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. Am J Roentgenol 2007;188:703-9.
54. Sawyer A, Saucier-Sawyer J, Booth C, Liu J, Patel T, Piepmeier J, et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res 2011;1:34-42.
55. Schinkel AH. P-Glycoprotein a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999;36:179-94.
56. Shahar T, Ram Z, Kanner AA. Covenction-enhance delivery catheter placements for high-grade gliomas: Complications and pitfalls. J Neurooncol 2012;107:373-8.
57. Strege RJ, Liu YJ, Kiely A, Johnson RM, Gillis EM, Storm P, et al. Toxicity and cerebrospinal fuid levels of carboplatin chronically infused into the brainstem of a primate. J Neurooncol 2004;67:327-34.
58. Stukel JM, Caplan MR. Targeted drug delivery for treatment and imaging of glioblastoma multiforme. Expert Opin Drug Deliv 2009;6:705-18.
59. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.
60. Thomale UW, Tyler B, Renard VM, Dorfman B, Guarnieri M, Haberl HE, et al. Local chemotherapy in the rat brainstem with multiple catheters: A feasibility study. Childs Nerv Syst 2009;25:21-8.
61. Vavra M, Ali MJ, Kang EW, Navalitloha Y Ebert A, Allen CV, et al. Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neuro Oncol 2004;6:104-12.
62. Varenika V, Dickinson P, Bringas J, LeCouteur R, Higgins R, Park J, et al. Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg 2008;109:874-80.
63. Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: Symposium review. J Neurooncol 2005;73:57-69.
64. Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, et al. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: Phase 1 study of fnal safety results. Neurosurgery 2007;61:1031-7.
65. Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003;54:479-87.
66. Wang CC, Li J, Teo CS, Lee T. The delivery of BCNU to brain tumors. J Control Release 1999;61:21-41.
67. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003;65:3-13.
68. Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003;64:125-37.
69. Weber FW, Floeth F, Asher A, Bucholz R, Berger M, Prados M, et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003;88:S93-103.
70. Wersall P, Ohlsson I, Biberfeld P, Collins VP, von Krusenstjerna S, Larsson S, et al. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunther 1997;44:157-64.
71. White E, Bienemann A, Megraw L, Bunnun C, Gill S. Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery. Cancer Gene Ther 2011;18:358-69.
72. White E, Bienemann A, Taylor H, Hopkins K, Cameron A, Gill S. A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme. Contemp Clin Trials 2012;33:320-31.